HIV and methamphetamine (MA) use disorder are commonly comorbid and individually associated with adverse health consequences, including frailty; however, less is known about the combined effects of both conditions. The current cross-sectional study examined how HIV and lifetime MA use disorder relate to frailty and explored associations between frailty and relevant clinical outcomes (i.e., neurocognitive and everyday functioning). Participants were categorized into three groups based on HIV status and lifetime MA diagnosis: HIV+/MA+ (n = 43), HIV+/MA− (n = 75), and HIV−/MA− (n = 92). A frailty index score (representing proportion of accumulated multisystem deficits) was calculated from 27 medical and psychiatric deficits. Multiple regression was used to examine frailty index score by HIV/MA group. Additional multiple regression models examined the interaction between frailty and HIV/MA group on cognitive and everyday functioning. Comorbid HIV+/MA+ participants had higher frailty index scores than both HIV−/MA− (b = −0.13, p < .001) and HIV+/MA− participants (b = −0.06, p = .007). Additional models linked higher frailty index score to worse global neurocognition (b = −17.6, p = .018) and greater likelihood of everyday functioning dependence (odds ratio = 1.56, p = .021). Although these relationships did not significantly differ by HIV/MA status, group-stratified analyses showed that associations of frailty with neurocognitive and everyday functioning were strongest among the HIV+/MA+ group. Multimodal public health interventions aimed at reducing frailty may help to decrease the likelihood of neurocognitive and everyday functioning problems. Current findings additionally lay groundwork for future longitudinal research examining whether frailty predicts onset of neurocognitive and functional decline in individuals with comorbid HIV and MA use disorder.
Get full access to this article
View all access options for this article.
References
1.
DarkeS, KayeS, McKetinR, DuflouJ: Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev, 2008; 27:253–262.
2.
HenryBL, MinassianA, PerryW: Effect of methamphetamine dependence on everyday functional ability. Addict Behav, 2010; 35:593–598.
3.
NordahlTE, SaloR, LeamonM: Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J Neuropsychiatry Clin Neurosci, 2003; 15:317–325.
4.
MaltaM, StrathdeeSA, MagnaniniMM, BastosFI: Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction, 2008; 103:1242–1257.
5.
DegenhardtL, MathersB, GuarinieriM, et al.: Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy, 2010; 21:347–358.
6.
ColfaxG, SantosGM, ChuP, et al.: Amphetamine-group substances and HIV. Lancet, 2010; 376:458–474.
7.
SantosGM, CoffinPO, DasM, et al.: Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco. J Acquir Immune Defic Syndr, 2013; 63:540–544.
8.
MooreDJ, BlackstoneK, WoodsSP, et al.: Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care, 2012; 24:1504–1513.
9.
ScottJC, WoodsSP, MattGE, et al.: Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev, 2007; 17:275–297.
10.
HeatonR, CliffordD, FranklinD, et al.: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 2010; 75:2087–2096.
11.
DeanAC, GromanSM, MoralesAM, LondonED: An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology, 2013; 38:259–274.
12.
LangfordD, AdameA, GrigorianA, et al.: Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr, 2003; 34:467–474.
13.
MaragosWF, YoungKL, TurchanJT, et al.: Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem, 2002; 83:955–963.
14.
RippethJD, HeatonRK, CareyCL, et al.: Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc, 2004; 10:1–14.
15.
CareyCL, WoodsSP, RippethJD, GonzalezR, HeatonRK, GrantI: Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav, 2006; 10:185–190.
16.
KesbyJP, HeatonRK, YoungJW, et al.: Methamphetamine exposure combined with HIV-1 disease or gp120 expression: Comparison of learning and executive functions in humans and mice. Neuropsychopharmacology, 2015; 40:1899–1909.
17.
WeberE, BlackstoneK, IudicelloJE, et al.: Neurocognitive deficits are associated with unemployment in chronic methamphetamine users. Drug Alcohol Depend, 2012; 125:146–153.
18.
MorganEE, DoyleKL, MinassianA, et al.: Elevated intraindividual variability in methamphetamine dependence is associated with poorer everyday functioning. Psychiatry Res, 2014; 220:527–534.
19.
BlackstoneK, IudicelloJE, MorganEE, et al.: Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med, 2013; 7:255–263.
20.
MitnitskiAB, MogilnerAJ, RockwoodK: Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal, 2001; 1:323–336.
21.
ButaBJ, WalstonJD, GodinoJG, et al.: Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev, 2016; 26:53–61.
22.
RockwoodK, MitnitskiA: Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci, 2007; 62:722–727.
23.
SearleSD, MitnitskiA, GahbauerEA, GillTM, RockwoodK: A standard procedure for creating a frailty index. BMC Geriatr, 2008; 8:24.
24.
SalemBE, NyamathiA, BrechtML, et al.: Constructing and identifying predictors of frailty among homeless adults-a latent variable structural equations model approach. Arch Gerontol Geriatr, 2014; 58:248–256.
25.
WingEJ: HIV and aging. International journal of infectious diseases: Int J Infect Dis, 2016; 53:61–68.
26.
GuaraldiG, BrothersTD, ZonaS, et al.: A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS, 2015; 29:1633–1641.
27.
OppenheimH, PaolilloEW, MooreRC, et al.: Neurocognitive functioning predicts frailty index in HIV. Neurology, 2018; 91:e162–e170.
28.
BlakerAL, Northrop NAB.K. Y: Chapter 30—Peripheral Influences of Methamphetamine Neurotoxicity. In: Neuropathology of Drug Addictions and Substance Misuse, Vol. 2 (Preedy VR, ed.) Academic Press, San Diego, 2016, pp. 309–319.
29.
VolkowND, FowlerJS, WangGJ, et al.: Distribution and pharmacokinetics of methamphetamine in the human body: Clinical implications. PLoS One, 2010; 5:e15269.
30.
AstaritaG, AvanesianA, GrimaldiB, et al.: Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis. PLoS One, 2015; 10:e0116961.
31.
BoylePA, BuchmanAS, WilsonRS, LeurgansSE, BennettDA: Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc, 2010; 58:248–255.
32.
BuchmanAS, BoylePA, WilsonRS, TangY, BennettDA: Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. Psychosom Med, 2007; 69:483–489.
33.
RobertsonDA, SavvaGM, KennyRA: Frailty and cognitive impairment—A review of the evidence and causal mechanisms. Ageing Res Rev, 2013; 12:840–851.
34.
Substance Abuse and Mental Health Services Administration (SAMHSA): Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. SAMHSA, Rockville, MD, 2012.
35.
MontoyaJL, CattieJ, MorganE, et al.: The impact of age, HIV serostatus and seroconversion on methamphetamine use. Am J Drug Alcohol Abuse, 2016; 42:168–177.
36.
MooreRC, PaolilloEW, HeatonA, FazeliPL, JesteDV, MooreDJ: Clinical utility of the UCSD Performance-Based Skills Assessment-Brief (UPSA-B) in adults living with HIV: Associations with neuropsychological impairment and patient-reported everyday functioning difficulties. PLoS One, 2017; 12:e0183614.
37.
MooreRC, HussainMA, WatsonCW, et al.: Grit and ambition are associated with better neurocognitive and everyday functioning among adults living with HIV. AIDS Behav, 2018; 22:3214–3225.
38.
Composite International Diagnostic Interview (CIDI, version 2.1) [computer program]. World Health Organization, Geneva, Switzerland, 1997.
39.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.
40.
HeatonR, MillerSW, TaylorMJ, GrantI: Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults.Psychological Assessment Resources, Lutz, FL, 2004.
41.
HeatonRK, TaylorM, ManlyJ: Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: TulskyD.S., HeatonR.K., CheluneG., IvnikR., BornsteinR.A., PrifiteraA., & LedbetterM. (Eds.), Clinical Interpretation of the WAIS-III and WMS-III. Academic Press, San Diego, CA, 2003. p. 181–210.
42.
NormanMA, MooreDJ, TaylorM, et al.: Demographically corrected norms for African Americans and Caucasians on the Hopkins verbal learning test–revised, brief visuospatial memory test–revised, Stroop color and word test, and Wisconsin card sorting test 64-card version. J Clin Exp Neuropsychol, 2011; 33:793–804.
43.
HeatonRK, MarcotteTD, MindtMR, et al.: The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc, 2004; 10:317–331.
44.
ObermeitLC, BeltranJ, CasalettoKB, et al.: Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): Defining “symptomatic” versus “asymptomatic” HAND. J Neurovirol, 2017; 23:67–78.
45.
DoyleKL, MorganEE, MorrisS, et al.: Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol, 2013; 19:565–573.
46.
AlthoffKN, JacobsonLP, CranstonRD, et al.: Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci, 2014; 69:189–198.
47.
DesquilbetL, JacobsonLP, FriedLP, et al.: HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci, 2007; 62:1279–1286.
48.
PiggottDA, MuzaaleAD, MehtaSH, et al.: Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One, 2013; 8:e54910.
49.
GuaraldiG, PalellaFJJr.: Clinical implications of aging with HIV infection: Perspectives and the future medical care agenda. AIDS, 2017; 31Suppl 2:S129–S135.
50.
JusticeAC, McGinnisKA, TateJP, et al.: Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend, 2016; 161:95–103.
51.
ChernerM, SuarezP, CaseyC, et al.: Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend, 2010; 106:154–163.
52.
ChernerM, BousmanC, EverallI, et al.: Cytochrome P450–2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings. J Int Neuropsychol Soc, 2010; 16:890–901.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
